Skip to main content
    V

    Vor Biopharma Inc (VOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.97
    -0.45 (-2.32%)

    Market Cap: $1.19B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vor Biopharma Inc (VOR) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    Vor Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$695.98M, operating cash flow was -$142.71M and free cash flow was -$143.65M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$86.73M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $371.64M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$0$0$0$0$0$91.00K$20.00K
    Gross profit$0$0$0$0$0$0-$91.00K-$20.00K
    Research and development$321.53M$93.31M$94.31M$64.55M$47.53M$31.62M$6.20M$2.43M
    Operating income-$371.64M-$121.19M-$126.04M-$93.42M-$69.02M-$43.37M-$10.42M-$2.86M
    Net income-$695.98M-$116.91M-$117.86M-$92.09M-$68.90M-$43.34M-$10.84M-$4.15M
    EBITDAN/A-$118.81MN/A-$90.91M-$67.58M-$42.76M-$10.14M-$2.84M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.69M$0$0$0$12.23M
    Gross profit$0$0$0-$23.00K$0$0$0-$865.00K$0$0$0-$892.00K
    Operating income-$58.44M-$47.85M-$35.16M-$35.96M-$28.11M-$274.28M-$33.29M-$31.31M-$28.51M-$29.04M-$32.33M-$28.12M
    Net income-$86.73M-$62.81M-$219.59M$1.72B-$812.68M-$1.57B-$32.49M-$30.71M-$27.56M-$27.84M-$30.80M-$26.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $280.00K by $396.21M. Shareholder equity was negative, at -$164.31M, as total liabilities of $628.44M exceeded total assets of $464.13M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$464.13M$142.89M$198.13M$299.37M$242.59M$75.91M$9.83M$1.01M
    Current assets$458.11M$96.51M$140.80M$236.95M$214.40M$49.11M$7.54M$936.00K
    Cash and equivalents$396.49M$81.95M$31.36M$57.71M$119.80M$48.54M$6.47M$929.00K
    Total liabilities$628.44M$46.23M$47.40M$48.76M$26.33M$27.64M$2.19M$7.77M
    Short-term debt$280.00K$4.21M$3.83M$3.27M$1.84M$863.00KN/A$4.46M
    Shareholder equity-$164.31M$96.66M$150.72M$250.61M$216.26M-$59.06M$7.64M-$6.77M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$496.31M$481.05M$506.75M$464.13M$176.24M$205.37M$109.31M$142.89M$115.99M$141.59M$167.03M$209.83M
    Total liabilities$633.49M$681.25M$657.17M$628.44M$2.40B$1.71B$43.24M$46.23M$43.04M$43.51M$43.99M$59.10M
    Cash and equivalents$78.98M$107.86M$169.87M$396.49M$160.46M$190.57M$50.05M$81.95M$52.80M$76.08M$44.96M$31.36M
    Shareholder equity-$137.17M-$200.20M-$150.42M-$164.31M-$2.23B-$1.51B$66.07M$96.66M$72.95M$98.08M$123.03M$150.72M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$142.71M-$99.66M-$100.29M-$85.14M-$69.14M-$36.29M-$9.86M-$2.66M
    Capital expenditures$941.00K$229.00K$1.07M$8.46M$3.89M$4.16M$748.00K$748.00K
    Free cash flow-$143.65M-$99.89M-$101.36M-$93.61M-$73.04M-$40.45M-$10.60M-$3.41M
    Share repurchasesN/AN/AN/AN/A$2.21M$0N/AN/A
    Investing cash flow-$48.80M$96.86M$71.01M-$94.09M-$91.65M-$4.16M-$748.00K-$748.00K
    Financing cash flow$503.81M$53.39M$2.94M$117.14M$232.91M$82.53M$17.70M$2.46M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$32.75M-$25.38M-$38.25M-$22.80M-$53.66M-$35.18M-$31.07M-$24.06M-$23.29M-$21.85M-$30.46M-$24.03M
    Capital expenditures$25.00K$120.00K$48.00K$314.00K$244.00K$152.00K$231.00K$72.00K$34.00K$9.00K$114.00K$111.00K
    Free cash flow-$32.77M-$25.50M-$38.29M-$23.11M-$53.91M-$35.34M-$31.30M-$24.14M-$23.32M-$21.86M-$30.58M-$24.14M
    Last 12 quarters

    Frequently Asked Questions About VOR

    What is Vor Biopharma's annual revenue?

    Vor Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Vor Biopharma profitable?

    No. Vor Biopharma reported net income of -$695.98M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does VOR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$142.71M minus capital expenditures of $941.00K produced free cash flow of -$143.65M.

    How much debt does Vor Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $280.00K and cash and equivalents of $396.49M.